Five compounds (the CRH1 receptor antagonist SB723620, the NK1 antagonist G597599, the SSRI/5HT2A agonist Vilazodone, the antidepressant 8-hydroxy-bupropion, and the type 4 phosphodiesterase inhbitor SB207499), provided by GlaxoSmithKline as part of The Emory-GSK-NIMH Collaborative Mood Disorders Initiative, will be evaluated for anti-fear and anxiolytic activity using fear-potentiated, light-enhanced, and CRH-enhanced startle paradigms (increased startle in the presence of cues that predict shock, during sustained illumination, or following i.c.v. corticotropin-releasing hormone infusions, respectively). Whereas light- and CRH-enhanced startle (which are more akin to anxiety than to fear) are mediated by circuitry that includes the bed nucleus of the stria terminalis (BNST) but not the central nucleus of the amygdala (CeA), fear-potentiated startle is mediated by circuitry that includes the CeA but not the BNST. A central goal of the proposed studies will be to identify differing pharmacological vulnerabilities associated with BNST (anxiety) versus CeA (fear) dependent behaviors. In humans, anxiety disorders are more prevalent in women than in men and, in rats, light-enhanced startle is more robust in females than in males. Interestingly, the BNST is sexually dimorphic in both species. Thus, a second goal will be to compare the influence of gender on BNST- versus CeA-dependent responses, and to evaluate gender influences on drug responses in each model. These same compounds will be evaluated in other laboratories (separate applications) using different behavioral models and non-behavioral assays. It is hoped that this integrated effort will foster new approaches for the rapid evaluation of novel compounds with potential clinical utility.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19MH069056-02
Application #
7553539
Study Section
Special Emphasis Panel (ZMH1)
Project Start
Project End
Budget Start
2004-07-01
Budget End
2005-06-30
Support Year
2
Fiscal Year
2004
Total Cost
$104,895
Indirect Cost
Name
Emory University
Department
Type
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Pape, Julius C; Carrillo-Roa, Tania; Rothbaum, Barbara O et al. (2018) DNA methylation levels are associated with CRF1 receptor antagonist treatment outcome in women with post-traumatic stress disorder. Clin Epigenetics 10:136
Hodgins, Gabrielle E; Blommel, Jared G; Dunlop, Boadie W et al. (2018) Placebo Effects Across Self-Report, Clinician Rating, and Objective Performance Tasks Among Women With Post-Traumatic Stress Disorder: Investigation of Placebo Response in a Pharmacological Treatment Study of Post-Traumatic Stress Disorder. J Clin Psychopharmacol 38:200-206
Dunlop, Boadie W; Binder, Elisabeth B; Iosifescu, Dan et al. (2017) Corticotropin-Releasing Factor Receptor 1 Antagonism Is Ineffective for Women With Posttraumatic Stress Disorder. Biol Psychiatry 82:866-874
Maples-Keller, Jessica L; Price, Matthew; Rauch, Sheila et al. (2017) Investigating Relationships Between PTSD Symptom Clusters Within Virtual Reality Exposure Therapy for OEF/OIF Veterans. Behav Ther 48:147-155
Guo, Ji-Dong; O'Flaherty, Brendan M; Rainnie, Donald G (2017) Serotonin gating of cortical and thalamic glutamate inputs onto principal neurons of the basolateral amygdala. Neuropharmacology 126:224-232
Norrholm, Seth Davin; Jovanovic, Tanja; Gerardi, Maryrose et al. (2016) Baseline psychophysiological and cortisol reactivity as a predictor of PTSD treatment outcome in virtual reality exposure therapy. Behav Res Ther 82:28-37
Price, Matthew; Maples, Jessica L; Jovanovic, Tanja et al. (2015) An investigation of outcome expectancies as a predictor of treatment response for combat veterans with PTSD: comparison of clinician, self-report, and biological measures. Depress Anxiety 32:392-9
Grillon, Christian; Hale, Elizabeth; Lieberman, Lynne et al. (2015) The CRH1 antagonist GSK561679 increases human fear but not anxiety as assessed by startle. Neuropsychopharmacology 40:1064-71
Ridgewell, Caitlin; Bray, Allison; Curtis, Kaylah et al. (2015) Enhanced Olfactory Cortex Connectivity in a Patient With PTSD With Olfactory Hallucinations. J Neuropsychiatry Clin Neurosci 27:e170-1
Stehouwer, Jeffrey S; Bourke, Chase H; Owens, Michael J et al. (2015) Synthesis, binding affinity, radiolabeling, and microPET evaluation of 4-(2-substituted-4-substituted)-8-(dialkylamino)-6-methyl-1-substituted-3,4-dihydropyrido[2,3-b]pyrazin-2(1H)-ones as ligands for brain corticotropin-releasing factor type-1 (CRF1) rec Bioorg Med Chem Lett 25:5111-4

Showing the most recent 10 out of 57 publications